(Q38270132)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25414121%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

review article

1 reference

title

Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25414121%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25414121%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

James R Taylor

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25414121%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

John G Gums

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25414121%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

1 reference

1 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25414121%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25414121%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25414121%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25414121%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

2141-2152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25414121%20AND%20SRC:MED&resulttype=core&format=json

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Standards of medical care in diabetes--2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

More patients get good diabetes control, but only a minority meet all goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Three-year efficacy of complex insulin regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Insulin degludec: overview of a novel ultra long-acting basal insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

The [pre-] history of the incretin concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Insulin-associated weight gain in diabetes--causes, effects and coping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Exenatide therapy in insulin-treated type 2 diabetes and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Patient preferences for noninsulin diabetes medications: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0325-2

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

21 January 2018

1 reference

12 December 2020

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with typ

1 reference

12 December 2020

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

12 December 2020

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

1 reference

12 December 2020

Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).

1 reference

12 December 2020

Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial

1 reference

12 December 2020

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)

1 reference

12 December 2020

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

1 reference

12 December 2020

Insulin management of type 2 diabetes mellitus

1 reference

12 December 2020

Glucagon-like peptide analogues for type 2 diabetes mellitus

1 reference

12 December 2020

The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes

1 reference

12 December 2020

10.1007/S40265-014-0325-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25414121%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

23 February 2020

1015151151

0 references

Fatcat ID

release_kk3m4tonmbcc7ot3vo33map6q4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kk3m4tonmbcc7ot3vo33map6q4

24 November 2022

mapped directly with Wikidata item

1 reference